Form 4: Erasca Director Alexander W. Casdin Acquires Stock Options in Lieu of 2025 Cash Compensation

Director Alexander W. Casdin of Erasca, Inc. acquired 28,877 stock options in lieu of cash compensation for his board service in 2025.

Summary

• Alexander W. Casdin, a director at Erasca, Inc., received 28,877 stock options on January 1, 2025.
• These options were granted in lieu of cash compensation for his service on the board of directors and its committees in 2025.
• The exercise price of the options is $2.51 per share.
• The options vest in monthly increments over 12 months, starting one month from the grant date, contingent on continued board service.
• The options expire on January 1, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating a positive alignment of interests between the director and the company. There are no negative implications.

Positives

• The acquisition of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages continued service on the board.

Industry Context

This is a standard practice for compensating board members, aligning their interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Granting stock options to board members is a common practice across the biotechnology industry.
• The vesting schedule of 12 months is typical for such grants.
• The exercise price is set at a specific value, which is standard for stock option grants.

Stakeholder Impact

• Shareholders may view this as a positive sign of alignment between management and company performance.
• The stock options provide an incentive for the director to contribute to the company's success.

Key Dates

Keywords

stock options, director compensation, insider trading, board of directors, equity, Erasca